

Supplement Documents for Results FY2005

Astellas Pharma Inc.

- Financial Results for FY2005
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

Consolidated results

*Figures for Mar 05 in this material are simple sums of those of former Yamanouchi and Fujisawa.

1.Detailed Information for Operating Results

billion yen, roundup under 0.1 billion yen					Forecasts			
	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Net Sales	862.0	879.3	17.3	2.0%	438.0	2.6%	902.0	2.6%
Cost of Sales	279.3	272.9	-6.3	-2.3%				
Ratio of Net Sales	32.4%	31.0%						
Gross Profit	582.6	606.3	23.6	4.1%				
SG&A	390.4	413.3	22.8	5.9%	102.0	81.9%	175.0	23.2%
Ratio of Net Sales	45.3%	47.0%						
Reserch and Development	127.6	142.0	14.4	11.3%				
SG&A excluding R&D	262.8	271.2	8.4	3.2%				
Advertising and Sales Promotion	62.5	79.4	16.9	27.1%				
Other	200.3	191.8	-8.4	-4.2%				
Operating Income	192.2	193.0	0.7	0.4%	68.0	-42.0%	180.0	-6.7%
Ratio of Net Sales	22.3%	22.0%			15.5%		20.0%	
Non Operating Income	13.1	14.8	1.7	13.0%				
Foreign Exchange Gain	0.5	3.9	3.3	640.1%				
Non Operating Expenses	11.1	5.3	-5.8	-52.5%				
Ordinary Income	194.2	202.5	8.3	4.3%	70.0	-42.6%	184.0	-9.2%
Ratio of Net Sales	22.5%	23.0%			16.0%		20.4%	
Special Gain	9.9	7.8	-2.0	-20.6%				
Special Loss	88.9	33.4	-55.4	-62.4%				
Merger Costs	60.3	21.2	-39.0	-64.7%				
Other	28.5	12.1	-16.4	-57.6%				
Income before Income Taxes	115.2	177.0	61.8	53.6%				
Income Taxes	54.3	71.7	17.3	31.9%				
Net Income	59.5	103.6	44.1	74.1%	54.0	-19.8%	123.0	18.7%
Ratio of Net Sales	6.9%	11.8%			12.3%		13.6%	

- Zepharma's results of 2H/Mar. 05 (Oct.1 - Mar. 31, 2005) are not included in net sales and operating income in Mar. 05 Full Year. (Due to equity method accounting)

- Extra shipment at the end of March, 2005 in preparation for a temporary stop of the ordering/distribution system in April following the merger contributed to sales and operating income, 11.9bil yen and 7.3 bil yen, respectively. Results for Mar. 06 include the negative impacts of the extra shipment.

2.Segment Information by Business

billion yen								
	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Sales Consolidated	862.0	879.3	17.3	2.0%	438.0	2.6%	902.0	2.6%
Pharmaceutical	841.8	869.8	28.0	3.3%	437.0	4.1%	900.4	3.5%
Ratio of Net Sales	97.7%	98.9%			99.8%		99.8%	
Rx	831.9	847.9	15.9	1.9%	437.0	6.6%	900.4	6.2%
Other	20.1	9.5	-10.6	-52.8%	1.0	-85.0%	1.6	-82.9%
Ratio of Net Sales	2.3%	1.1%			0.2%		0.2%	

- Zepharma's results of 2H/Mar. 05 (Oct.1 - Mar. 31, 2005) are not included in net sales and pharmaceutical sales in Mar. 05 Full Year. (Due to equity method accounting)

Results for Mar. 06 include the negative impacts of the extra shipment.

3.Overseas Sales

billion yen								
	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Overseas Sales	358.6	398.2	39.6	11.1%	208.1	7.7%	422.9	6.2%
Ratio of Net Sales	41.6%	45.3%			47.5%		46.9%	
North America	172.2	191.9	19.7	11.4%				
Ratio of Net Sales	20.0%	21.8%						
Europe	154.8	172.2	17.4	11.2%				
Ratio of Net Sales	18.0%	19.6%						
Asia	31.5	34.0	2.5	8.0%				
Ratio of Net Sales	3.7%	3.9%						

4. Segment Information by Region

billion yen

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Sales	862.0	879.3	17.3	2.0%
Japan	529.6	511.1	-18.4	-3.5%
Ratio of Net Sales	61.4%	58.1%		
North America	129.7	145.3	15.5	12.0%
Ratio of Net Sales	15.1%	16.5%		
Europe	186.4	203.2	16.8	9.0%
Ratio of Net Sales	21.6%	23.1%		
Asia	16.2	19.6	3.4	21.1%
Ratio of Net Sales	1.9%	2.2%		
Operating Income	192.2	193.0	0.7	0.4%
Japan	161.1	138.1	-22.9	-14.3%
Ratio of Net Sales	83.8%	71.6%		
North America	23.0	32.7	9.6	41.7%
Ratio of Net Sales	12.0%	17.0%		
Europe	11.7	18.3	6.6	56.1%
Ratio of Net Sales	6.1%	9.5%		
Asia	2.3	3.8	1.5	65.2%
Ratio of Net Sales	1.2%	2.0%		
Eliminations	-6.1	-0.0	6.0	

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
438.0	2.6%	902.0	2.6%
246.3	-1.5%	509.7	-0.3%
56.2%		56.5%	
79.9	16.6%	168.0	15.6%
18.2%		18.6%	
101.2	2.3%	202.3	-0.4%
23.1%		22.4%	
10.6	15.0%	22.0	12.1%
2.4%		2.4%	
68.0	-42.0%	180.0	-6.7%

5. Exchange Rate (Average Rate)

yen

	Mar 05 Full Year	Mar 06 Full Year
Yen/USD	108	113
Yen/EUR	135	138

Mar 07 1H
110
140

Mar 07 Full Year
110
140

6. Per share information

	Mar 05 Full Year	Mar 06 Full Year
The number of share issued (thousand)*	571,428	573,949
Treasury Stocks (thousand)*		15,639
The number of share issued deducting Treasury Stock*		558,309
Earnings per share (Yen)		183.88
Dividend per share (Yen)		70
Dividend on Earnings (%)		3.3%

Mar 07 Full Year

220.31
80

* As of March 31

7. Research and Development Expenses billion yen

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Research and Development	127.6	142.0	14.4	11.3%
Ratio of Net Sales	14.8%	16.2%		
Parent	92.4	109.2	16.8	18.2%

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
102.0	81.9%	175.0	23.2%
23.3%		19.4%	
91.0	123.4%	148.0	35.4%

8. Addition to Property, Plant and Equipment billion yen

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Addition to Property, Plant and Equipment				
Consolidated	23.4	19.6	-3.7	-16.0%
Parent	11.3	7.6	-3.7	-32.8%
Depreciation(Tangible)				
Consolidated	26.1	27.3	1.1	4.5%
Parent	12.9	9.8	-3.1	-24.0%
Depreciation(Intangible)				
Consolidated	8.7	9.9	1.1	13.3%
Parent	4.6	4.4	-0.1	-3.3%

Mar 07 Full Year	Change (%)
29.0	47.3%
7.5	-1.4%
26.6	-2.7%
8.2	-16.6%
10.5	5.7%
4.8	7.9%

9. Employee

	Mar 06 Beginning	Mar 06 Ending
Total	15,500	15,000
Japan	9,500	8,900
North America	1,700	1,700
Europe	3,500	3,600
Asia	900	900
Total Medical Representatives	4,700	4,800

* Increase in Europe is due to the change of the way to count the number of employees.
On actual basis, the number of employees in Europe decreased compared to April 1, 05.

10. Shareholders

	Mar 06 Beginning	Mar 06 Ending
Bank	39.5%	37.0%
Securities	2.3%	1.6%
Other companies	4.1%	3.5%
Foreign companies	44.9%	47.3%
Individuals and others	8.4%	7.8%
Treasury Stock	0.8%	2.7%

* Component ratio for Mar 06 Beginning are pro forma figures calculated based on a component ratio of former Yamanouchi and Fujisawa at the end of Mar 05.

11.Detailed Pharmaceutical Segment Information

1)Consolidated sales of major products

billion yen

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Prograf	122.8	145.9	23.0	18.8%	77.3	10.9%	160.8	10.2%
Sales by Astellas	118.0	140.1	22.1	18.8%	75.1	12.6%	156.8	11.9%
Japan*	10.5	14.2	3.7	35.2%	8.2	25.1%	17.1	19.5%
North America	63.5	74.5	11.0	17.3%	38.6	9.6%	81.7	9.5%
Europe	38.4	43.4	4.9	12.9%	24.1	12.9%	49.5	13.9%
Asia	5.4	7.8	2.4	44.8%	4.1	17.9%	8.6	9.9%
Exports to third parties(Europe)	4.8	5.8	0.9	19.4%	2.2	-27.6%	4.0	-31.2%
Harnal	135.9	137.8	1.8	1.3%	57.4	-16.9%	113.9	-17.3%
Sales by Astellas	98.8	100.3	1.4	1.5%	40.6	-21.7%	79.4	-20.9%
Japan	49.4	44.9	-4.5	-9.2%	21.1	-11.7%	41.1	-8.6%
Europe	44.8	49.5	4.6	10.3%	16.6	-34.4%	32.2	-35.0%
Capsule	44.0	36.1	-7.8	-17.9%	7.4	-64.2%	12.7	-64.8%
Omnicon OCAS	0.8	13.3	12.4	1500.5%	9.1	102.6%	19.5	46.0%
Asia	4.5	5.9	1.4	31.2%	3.0	8.5%	6.2	4.1%
Bulk and Royalties(Europe)	37.0	37.4	0.3	0.9%	16.8	-2.4%	34.5	-7.9%
Vesicare	2.7	14.8	12.0	439.0%	13.1	158.6%	29.6	99.2%
North America	1.1	7.7	6.5	545.7%	6.9	205.0%	15.8	104.4%
Europe	1.5	7.1	5.5	357.2%	6.2	121.3%	13.8	93.6%
Funguard/Mycamine	13.8	15.2	1.4	10.5%	9.0	15.8%	18.7	22.8%
Japan*	13.8	14.0	0.2	1.5%	7.2	-1.9%	14.0	-0.1%
North America	-	1.2	1.2	-	1.8	301.3%	4.7	283.0%
Protopic	21.4	14.4	-7.0	-32.7%	8.4	26.8%	17.3	20.1%
Japan*	2.6	2.6	0.0	0.9%	1.3	-1.6%	2.6	-1.0%
North America	12.9	6.5	-6.3	-49.2%	4.0	45.1%	8.2	24.9%
Europe	5.5	4.9	-0.5	-10.7%	2.7	17.5%	6.0	20.1%
Asia	0.4	0.2	-0.1	-27.8%	0.3	90.0%	0.6	100.8%

- Mar 05 sales of products marked by * in Japan are shown on a net sales basis,

while those of other products are on a gross sales basis. Mar 06 and Mar 07 figures of all products are on a gross sales basis.

2) Consolidated Sales of Other Products

billion yen

Rx Sales in Japan	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Lipitor	85.5	91.5	5.9	7.0%	47.2	8.6%	95.3	4.1%
Gaster	73.1	68.8	-4.2	-5.8%	33.0	-2.6%	65.5	-4.9%
Micardis	26.1	37.3	11.1	42.8%	23.7	43.2%	50.0	33.9%
Cefzon*	17.7	18.4	0.6	3.4%	7.6	-11.8%	16.4	-10.9%
Myslee*	13.3	17.1	3.7	28.4%	9.7	18.5%	20.2	17.7%
Vaccines	11.7	14.1	2.3	19.9%	1.6	-54.7%	13.2	-6.4%
Seroquel*	13.1	15.2	2.1	16.6%	8.6	15.5%	17.4	13.8%
Frandol	13.4	12.7	-0.7	-5.5%	6.3	-0.2%	12.4	-2.7%
Perdipine	10.5	8.9	-1.6	-15.2%	4.0	-9.4%	8.1	-9.9%
Luvox*	8.7	10.3	1.5	17.4%	5.7	14.0%	11.6	12.3%
Dorner	9.3	8.5	-0.7	-8.1%	4.0	-5.6%	8.0	-6.5%
Dogmatyl*	7.5	7.8	0.2	3.0%	3.8	-3.3%	7.5	-4.0%
Cefamezin*	7.1	7.5	0.3	4.4%	3.5	-6.5%	6.9	-8.1%
Targocid*	6.4	7.0	0.6	10.3%	3.7	6.7%	7.6	7.3%
Intal*	11.8	8.4	-3.4	-28.9%	3.7	15.5%	8.5	0.7%
Nivadil*	7.6	6.7	-0.8	-11.6%	3.0	-13.9%	5.7	-15.2%
Cibenol*	4.7	5.1	0.3	6.9%	2.7	6.0%	5.4	5.6%
Nasea	4.0	4.4	0.4	10.0%	2.4	10.4%	4.8	6.7%
Starsis	4.5	4.3	-0.1	-4.0%	2.2	-0.9%	4.5	2.4%
Total Rx Sales In Japan	463.4	440.4	-23.0	-5.0%	225.5	6.4%	467.2	6.1%

- Mar 05 sales of products marked by "*" in Japan are shown on a net sales basis, while those of other products are on a gross sales basis. Mar 06 and Mar 07 figures of all products are on a gross sales basis.

- Sales of Vaccines for Mar 05 are sums of ex-Yamanouchi and ex-Fujisawa.

- Extra shipment at the end of Mar 05 for the merger contributed to sales by 11.9bil yen.

Results of Mar 06 include the negative impacts of the shipment.

The impacts of the extra shipment on main products:

Gaster 2.0 bil yen, Harnal 1.5 bil yen, Lipitor 3.0 bil yen, Micardis 2.0 bil yen

RX Sales in North America and EU	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Adenoscan (North America)	33.0	35.3	2.2	7.0%	17.3	-1.3%	35.8	1.1%
AmBisome (North America)	8.7	8.9	0.1	1.6%	4.1	-9.1%	8.0	-10.3%
Vaprisol (North America)	-	0.2	0.2	-	0.1	-	0.3	45.6%
Amevive (North America)	-	-	-	-	2.0	-	5.0	-
Eligard (Europe)	1.4	2.6	1.2	86.4%	2.8	166.8%	6.8	157.5%

Export Sales	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)	Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
Cefzon Overseas(Exports to third party)	5.7	10.9	5.1	88.4%	6.4	-5.4%	10.4	-4.5%
Cefspan Overseas(Exports to third party)	5.0	6.0	0.9	18.1%	2.9	-16.3%	5.7	-4.6%

Sales in Europe and North America

		Unit:M\$			
North America		Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Sales		1,206	1,282	76	6.3%
Prograf		590	658	67	11.4%
Adenoscan		307	312	4	1.6%
AmBisome		81	78	-2	-3.5%
Protopic		119	57	-62	-51.7%
VESicare		11	68	56	512.7%
Mycamine		-	10	10	-
Adenocard		16	5	-11	-70.1%
Vaprisol (Launched in Mar 2006)		-	2	2	-
Amevive (Licensed in Apr 2006)		-	-	-	-

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
726	16.1%	1,527	19.1%
351	9.1%	743	12.8%
157	-1.8%	325	4.1%
37	-9.6%	73	-7.6%
37	44.4%	75	28.7%
62	203.6%	143	110.6%
17	299.4%	43	294.5%
1	-74.3%	3	-40.0%
1	-	3	50.0%
19	-	46	-

		Unit:ME			
Europe		Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Sales		1,378	1,474	95	6.9%
Harnal		606	630	24	4.0%
Sales by Astellas		332	359	27	8.2%
Capsule		326	263	-63	-19.5%
OCAS		6	96	90	1469.5%
Bulk and Royalty		274	271	-2	-1.0%
Prograf		319	357	37	11.9%
Sales by Astellas		283	314	31	11.1%
Exports to third parties		36	42	6	17.6%
Vesicare		11	51	40	348.3%
Protopic		40	35	-4	-12.1%
Eligard		10	19	8	82.8%

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
723	-0.8%	1,445	-2.0%
238	-23.9%	476	-24.5%
118	-36.5%	230	-36.0%
53	-65.3%	91	-65.4%
65	96.3%	139	43.7%
120	-5.4%	246	-9.3%
188	4.6%	382	6.9%
172	9.4%	353	12.2%
16	-29.8%	29	-32.2%
44	114.4%	99	90.7%
20	13.8%	43	18.2%
20	158.6%	49	153.6%

Sales of Zepharm (OTC subsidiary)

		billion yen			
		Mar 05 Ending	Mar 06 Ending	Change	Change (%)
Sales		22.4	21.9	-0.5	-2.5%

- Sales of Mar. 05 Full Year: Sums of aggregated 1H OTC sales of former Yamanouchi and Fujisawa and 2H sales of Zepharm.

12 Consolidated Balance Sheets

Billion yen

	31-Mar-06		31-Mar-05		Change	Remarks
	Amount	Composition	Amount	Composition		
Assets	1,584.5	100.0%	1,469.7	100.0%	114.7	
Current assets	1,050.3	66.3%	961.7	65.4%	88.5	
Cash on hand and in banks	178.1		405.3		-227.2	- Mainly due to Investment on CP
Trade notes and accounts receivable	227.2		220.6		6.5	
Marketable securities	445.3		142.3		302.9	- Mainly due to Investment on CP
Inventories	93.8		90.6		3.2	
Deferred tax assets	56.0		58.9		-2.8	
Other	50.2		44.2		5.9	
Allowance for doubtful receivable	-0.5		-0.4		0.0	
Fixed assets	534.2	33.7%	508.0	34.6%	26.2	
Property, plant and equipment	206.5		222.6		-16.0	
Buildings and structures	99.2		102.3		-3.0	
Machinery, equipment and vehicles	37.2		43.8		-6.5	
Tools, furniture and fixtures	28.3		28.7		-0.4	
Land	35.0		38.9		-3.9	
Construction in progress	6.3		7.4		-1.0	
Other	0.2		1.2		-0.9	
Intangible fixed assets	31.5		35.6		-4.1	- Due to impairment etc.
Investments and other assets	296.1		249.7		46.3	
Investment securities	242.1		182.9		59.2	- Due to investment on bonds etc.
Long-term loans receivable	2.3		1.7		0.5	
Deferred tax assets	16.4		25.8		-9.4	
Other	35.5		39.4		-3.9	
Allowance for doubtful receivables	-0.3		-0.2		-0.1	

	31-Mar-06		31-Mar-05		Change	Remarks
	Amount	Composition	Amount	Composition		
Liabilities and Shareholders' Equity	1,584.5	100.0%	1,469.7	100.0%	114.7	
Liabilities	367.1	23.2%	316.2	21.5%	50.9	
Current liabilities	300.2	19.0%	243.6	16.6%	56.5	
Trade notes and accounts payable	62.5		52.7		9.7	
Short-term loans payable	0.4		2.0		-1.6	
Other accounts payable	130.4		73.3		57.0	- Due to unsettled account payable for securities
Accrued expenses	50.8		62.0		-11.2	
Accrued income taxes	40.0		28.3		11.6	
Accrued consumption taxes	1.1		1.4		-0.2	
Deferred tax liabilities	0.0		0.1		-0.1	
Allowance for sales rebates and others	5.8		5.0		0.8	
Other	9.0		18.4		-9.3	
Long-term liabilities	66.9	4.2%	72.5	4.9%	-5.6	
Convertible bonds	0.0		5.0		-4.9	- Due to conversion in to common shares
Long-term loans payable	0.5		0.4		0.1	
Deferred tax liabilities	1.4		7.2		-5.8	
Accrued retirement benefits for employees	40.6		34.8		5.7	
Accrued retirement benefits for directors	0.0		1.0		-0.9	
Other	24.2		23.9		0.3	
Minority interests	0.4	0.0%	1.7	0.1%	-1.2	
Shareholders' equity	1,216.8	76.8%	1,151.8	78.4%	65.0	
Common stock	102.9	6.5%	144.7	9.9%	-41.7	
Additional paid-in capital	176.8	11.2%	177.3	12.1%	-0.5	
Retained earnings	959.2	60.5%	938.8	63.9%	20.4	
Unrealized holding gain on securities	44.2	2.8%	25.5	1.7%	18.7	
Translation Adjustments	-4.3	-0.3%	-19.2	-1.3%	14.8	
Treasury Stock	-61.9	-3.9%	-115.3	-7.9%	53.4	

* Changes in Shareholder's equity are mainly due to merger accounting.

13.Detailed Parent Company Information

P/L

billion yen

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Sales	625.7	576.0	-49.6	-7.9%
Cost of Sales	234.4	217.5	-16.9	-7.2%
Ratio of Net Sales	37.5%	37.8%		
Gross Profit	391.2	358.4	-32.7	-8.4%
SG&A	242.9	233.4	-9.5	-3.9%
Ratio of Net Sales	38.8%	40.5%		
Reserch and Development	92.4	109.2	16.8	18.2%
Operating Income	148.2	125.0	-23.2	-15.7%
Ratio of Net Sales	23.7%	21.7%		
Non Operating Income	28.3	37.7	9.3	33.0%
Non Operating Expenses	7.1	3.5	-3.5	-50.1%
Ordinary Income	169.5	159.2	-10.3	-6.1%
Ratio of Net Sales	27.1%	27.6%		
Special Gain	8.5	5.6	-2.8	-33.7%
Special Loss	68.5	17.2	-51.3	-74.8%
Merger Costs	45.7	9.8	-35.9	-78.5%
Other	22.8	7.4	-15.4	-67.5%
Income before Income Taxes	109.5	147.6	38.0	34.8%
Income Taxes	34.6	46.1	11.4	33.0%
Net Income	74.8	101.4	26.6	35.6%
Ratio of Net Sales	12.0%	17.6%		

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
289.0	0.5%	595.0	3.3%

91.0	123.4%	148.0	35.4%
28.0	-65.4%	97.0	-22.4%
9.7%		16.3%	

30.0	-63.1%	99.0	-37.8%
10.4%		16.6%	

33.0	-36.4%	76.0	-25.1%
11.4%		12.8%	

Sales of Parent company

	Mar 05 Full Year	Mar 06 Full Year	Change	Change (%)
Rx	473.6	446.4	-27.1	-5.7%
Exporting sales	129.2	125.1	-4.0	-3.1%
Royalty	29.6	32.9	3.2	11.1%
OTC	9.8	-	-9.8	-100.0%
Other	13.0	4.3	-8.6	-66.5%

Mar 07 1H	Change (%)	Mar 07 Full Year	Change (%)
228.2	5.9%	473.4	6.0%
60.8	-10.9%	121.6	-2.9%
17.4	16.4%	35.9	9.0%